Overview:
Pre-Operative ProfileIntroduction: The Pre-Operative Profile is a diagnostic tool designed for comprehensive pre-surgical screening using serum and whole blood samples. Associated with conditions like anemia and liver dysfunction, these disorders present with fatigue, jaundice, and severe complications if untreated, particularly in individuals preparing for surgery. Per the 2023 Biochemistry, Hematology, Serology, and Clinical Pathology guidelines, the test employs biochemistry, hematology, serology, and clinical pathology with spectrophotometry, automated cell counter, and immunoassay technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for surgical preparation in clinical settings. This diagnostic falls under pre-operative evaluation and targets individuals scheduled for surgery, addressing the challenge of accurate health assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its dual-sample approach ensures reliable detection.
Other Names: Pre-Op Pfl.
FDA Status: FDA approved, CLIA certified for biochemistry, hematology, serology, and clinical pathology, compliant with 2025 standards.
Historical Milestone: Introduced in the 1980s by surgical labs, this test advanced pre-operative screening.
Purpose: The test screens for 33 parameters including hemoglobin to guide pre-operative assessment, assess overall health and infectious status, and inform treatment and prevention strategies.
Test Parameters: 1. Hemoglobin, 2. RBC Count, 3. WBC Count, 4. Platelet Count, 5. ESR, 6. Peripheral Smear, 7. Total Bilirubin, 8. AST, 9. ALT, 10. ALP, 11. Total Protein, 12. Albumin, 13. Globulin, 14. Creatinine, 15. Urea, 16. Sodium, 17. Potassium, 18. Chloride, 19. Calcium, 20. Phosphorus, 21. Fasting Glucose, 22. HbA1c, 23. PT, 24. INR, 25. APTT, 26. HBsAg, 27. Anti-HCV, 28. HIV 1 & 2, 29. Blood Group, 30. Urine Routine, 31. ECG, 32. Chest X-Ray, 33. TSH.
Pretest Condition: Fasting 10-12 hours required; patients should report fatigue, jaundice, or recent health symptoms.
Specimen: 3 mL serum in 1 SST, 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours (Serum), 48 hours (Blood) with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days (Serum, Blood) at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months (Serum) at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on fatigue, jaundice, prior health reactions, or family history of chronic diseases, as well as any recent trauma or treatments.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated conditions including surgical complications, benefits of early detection, and minimal discomfort from sample collection.
Procedural Considerations: The test involves sample processing using spectrophotometry, automated cell counter, and immunoassay and interpret results within 1-2 days using provided controls.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent medication use can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Abnormal results indicate possible pre-operative risks, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist.
Specialist Consultation: General practitioners or specialists in surgery or internal medicine should be consulted for case management, treatment planning, and coordination with health programs.
Additional Supporting Tests: Imaging or specific panels for confirmation.
Test Limitations: The test may produce false negatives in early disease stages or false positives in acute illness, requiring a comprehensive diagnostic approach that includes clinical correlation.
References: Biochemistry, Hematology, Serology, and Clinical Pathology Guidelines 2023, Journal of Surgical Research 2024, Chemistry 2025.
